Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
| ▸ | GABRE | P78334 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.35 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.35 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14506000 | 0.74 | — | — | |
| SCHEMBL3362598 | 0.74 | — | — | |
| SCHEMBL68915 | 0.73 | TSHR (0.33) | TSHRPMP22GABRPGABRDGABRA1 | |
| SCHEMBL2807157 | 0.73 | TSHR (0.33) | TSHRPMP22GABRPGABRDGABRA1 | |
| SCHEMBL6837486 | 0.72 | ERN1 (0.35) | TSHRPMP22GABRPGABRDGABRA1 | |
| SCHEMBL337230 | 0.70 | — | — | |
| SCHEMBL1847750 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL720508 | 0.69 | SLC6A1 (0.38) | TSHRPMP22GABRPGABRDGABRA1 | |
| SCHEMBL28613071 | 0.69 | KDM4E (0.34) | TSHRPMP22GABRPGABRDGABRA1 | |
| SCHEMBL28844168 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108558589-B | Process for the manufacture of nitriles and their corresponding amines | 中国石化扬子石油化工有限公司 | 2022-02-08 | — | — | CN | claimed |
| WO-2009018368-A1 | COMBINATION TREATMENT OF NMDA (N-METHYL-D-ASPARTATE)-ENHANCER, GLYCINE TRANSPORTER INHIBITOR, D-AMINO ACID OXIDASE INHIBITOR (DAAOI) FOR NEUROPSYCHIATRIC DISORDERS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2009-02-05 | — | — | WO | claimed |
| US-11529342-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3006023-B1 | SORBIC ACID AND DERIVATIVES THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20190151301-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3006024-B1 | BENZOIC ACID OR SALTS THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10149845-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2018-12-11 | — | — | US | disclosed |
| US-10039730-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170189358-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170181989-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2017-06-29 | — | — | US | disclosed |
| US-9675604-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2017-06-13 | — | — | US | disclosed |
| US-20100189818-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2010085452-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR - UCLA MEDICAL CENTER (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2009018368-A1 | COMBINATION TREATMENT OF NMDA (N-METHYL-D-ASPARTATE)-ENHANCER, GLYCINE TRANSPORTER INHIBITOR, D-AMINO ACID OXIDASE INHIBITOR (DAAOI) FOR NEUROPSYCHIATRIC DISORDERS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2009-02-05 | — | — | WO | disclosed |
| CN-1568370-A | treatment of central nervous system disorders with D-amino acid oxidase and D-aspartate oxidase antagonists | GENSET SA (FR) | 2005-01-19 | — | — | CN | disclosed |
| EP-1412515-A2 | TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS | Genset (FR) | 2004-04-28 | — | — | EP | disclosed |
| US-20030185754-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | GENSET, S.A. (FR) | 2003-10-02 | — | — | US | disclosed |
| US-20030166554-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | GENSET, S.A. (FR) | 2003-09-04 | — | — | US | disclosed |
| WO-2003047558-A2 | TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE INHIBITORS | GENSET S.A. (FR) | 2003-06-12 | — | — | WO | disclosed |
| WO-2002066672-A2 | TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS | GENSET S.A. (FR) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030185754-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | DDO, DAO, XDH | TSHR 2169/4885PMP22 364/4885GABRP 109/4885 |
| US-20030166554-A1 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | DDO, DAO, XDH | TSHR 2169/4885PMP22 364/4885GABRP 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.